Saturday 17 October 2026
Export RVMD’s income statement to Excel — free account
Revolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022. In the quarter to June 2026, EPS fell 133.6%, free cash flow fell 70.0% and total debt rose 322.7%, each against the same quarter a year earlier.
177.96
11.30
−5.97%
Follow RVMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (79.09%) | (76.67%) | (58.07%) | (60.76%) |
+8 more TTM periods Free account |
|
| (52.37%) | (59.39%) | (46.06%) | (47.87%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(47.68%) | (80.23%) | (62.23%) | (54.45%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(5.84) | (5.41) | (4.81) | (4.11) | |
Free Cash Flow |
(1,232.13) | (1,071.73) | (913.73) | (777.08) | |
Capital Expenditures |
(9.10) | (14.26) | (15.99) | (15.29) | |
| Other line items | |||||
Cash ROIC |
(16.25%) | (29.05%) | (23.28%) | (20.53%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(27.42) | (38.07) | (33.61) | (30.74) | |
Operating CF/Net income |
0.69 | 0.77 | 0.79 | 0.79 | |
Depreciation/Fixed assets |
0.01 | (0.12) | (0.34) | (0.51) | |
Capex/Depreciation |
(36.69) | 3.69 | 1.42 | 0.91 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.80) | (5.34) | (4.72) | (4.03) | |
Capex per Share |
(0.04) | (0.07) | (0.08) | (0.08) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates